XML 91 R74.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Commitments and Contingencies (Actions In Which We Are The Plaintiff) (Details) |  | 1 Months Ended | 2 Months Ended | 3 Months Ended
--- | --- | --- | --- | ---
Aug. 10, 2017 Patents | Oct. 31, 2017 Patents | Sep. 30, 2017 Patents | Jul. 31, 2017 Patents | Mar. 31, 2017 Patents | Feb. 28, 2017 Patents | Jan. 31, 2017 Patents | Aug. 31, 2016 Patents | Jul. 31, 2016 Patents | Jan. 31, 2016 Patents | Dec. 31, 2015 Patents | Jul. 31, 2015 Defendant | Jun. 30, 2015 Patents | Jan. 31, 2015 Patents | Jun. 30, 2013 Patents | Jul. 31, 2015 Defendant | Apr. 30, 2017 Patents Defendant
Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents not infringed upon |  |  |  |  |  |  |  |  |  |  |  |  | 4 |  |  |  |
Precedex Premix [Member] | Hospira Versus Fresenius [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents not infringed upon |  |  |  |  |  |  |  |  |  |  | 4 |  |  |  |  |  |
Precedex Premix [Member] | Hospira Versus Par [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents not infringed upon |  |  |  |  |  |  |  | 4 |  |  |  |  |  |  |  |  |
Patent Infringement [Member] | Bosulif [Member] | Wyeth Versus Sun [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Mylan Laboratories Limited [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  |  |  |  |  |  |  |  | 5 | 5 |  |  |  | 5 |  |  |
Number of patents infringed upon |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 |  |
Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Mylan Laboratories Limited [Member] | Judicial Ruling [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents not infringed upon |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents infringed upon | 5 |  |  |  |  | 5 | 5 |  |  |  |  |  |  |  |  |  |
Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of defendants | Defendant |  |  |  |  |  |  |  |  |  |  |  | 4 |  |  |  |  |
Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Settled Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of defendants | Defendant |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 |
Patent Infringement [Member] | Toviaz Composition-of-matter Patents [Member] | Pfizer Versus Mylan Laboratories Limited [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents infringed upon |  |  |  |  |  |  |  |  |  | 3 |  |  |  | 3 |  |  |
Patent Infringement [Member] | Toviaz Composition-of-matter Patents [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents infringed upon |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |
Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus MicroLabs [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |
Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Zydus [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |
Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Prinston and Breckenridge [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |
Patent Infringement [Member] | Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3
Number of defendants | Defendant |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25
Patent Infringement [Member] | Bavencio [Member] | Pfizer Versus BMS, E.R. Squibb & Sons, Ono Pharmaceutical and Tasuku Honjo [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Member] | Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Breckenridge [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents due to expire in December 2020 |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number or patents due to expire in December 2025 |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Gain Contingency, Number of Defendants + References No definition available. + Details
Name: | pfe_GainContingencyNumberofDefendants
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2020 + References No definition available. + Details
Name: | pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2025 + References No definition available. + Details
Name: | pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_GainContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of entity's patents that another entity has allegedly infringed. + References No definition available. + Details
Name: | us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of entity's patents that another entity was found to have infringed. + References No definition available. + Details
Name: | us-gaap_GainContingencyPatentsFoundInfringedUponNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of entity's patents that another entity was found not to have infringed. + References No definition available. + Details
Name: | us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References No definition available. + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_PrecedexPremixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_HospiraVersusAmnealPharmaceuticalsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_HospiraVersusFreseniusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_HospiraVersusParMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_BosulifMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_WyethVersusSunMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_ToviazMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_PfizerVersusSeveralGenericManufacturersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_ToviazCompositionofmatterPatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_XeljanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_PfizerVersusMicroLabsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_PfizerVersusZydusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_PfizerVersusPrinstonandBreckenridgeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentInfringementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_BavencioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=pfe_PfizerVersusBreckenridgeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |